Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT-3724 + gemcitabine + oxaliplatin
- Development stage
- Discontinued
- Lead developer
- Molecular Templates
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MT-3724 + gemcitabine + oxaliplatin is a **combination therapy** evaluated for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other B-cell non-Hodgkin lymphomas. MT-3724 is an engineered toxin body (ETB) consisting of a CD20-specific single-chain variable fragment (scFv) genetically fused to a modified Shiga-like toxin 1A subunit, designed to selectively target and kill CD20-expressing B cells via internalization and ribosome inactivation, inhibiting protein synthesis and inducing apoptosis. Gemcitabine is a nucleoside analogue that inhibits DNA synthesis, and oxaliplatin is a platinum-based chemotherapeutic that induces DNA cross-linking and apoptosis. The combination has shown high response rates (ORR 85.7%) in early trials, with limitations due to capillary leak syndrome.
- Other names
- MT-3724 + GEMOXMT-3724 combined with gemcitabine and oxaliplatinMT3724 combined with gemcitabine and oxaliplatinMT 3724 combined with gemcitabine and oxaliplatin
02
Targets
60S (Eukaryotic 60S ribosomal subunit)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on MT-3724 + gemcitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT-3724 + gemcitabine + oxaliplatin.